Can a new vaccine safely shield babies from meningitis?

NCT ID NCT06389513

Completed Prevention Sponsor: CanSino Biologics Inc. Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial is testing the safety of the Menhycia® vaccine in about 3,000 healthy 3-month-old infants who have not yet received any epidemic meningitis vaccine. The infants will receive three doses of the vaccine at least one month apart, with an optional booster at 12 months of age. Researchers will monitor for any local or systemic side effects, such as fever or injection-site reactions, to ensure the vaccine is safe for this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Menhycia® (MCV4) vaccine
What this could lead to: If successful, this could confirm that Menhycia® is safe for routine use in young infants, helping protect them against epidemic meningitis.
What could go wrong: This is a safety-focused study, not designed to measure effectiveness. Possible side effects include local reactions like redness or swelling, and systemic reactions like fever.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPIDEMIC MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningococcal meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPIDEMIC MENINGITIS

Contacts and locations

Locations

Nanjing Luhe District Center for Disease Control and Prevention Center for Disease Control and Prevention

Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.